Association of VEGFA-2578 C&gt;A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients

Mendonça, Guilherme Rossi Assis de; Brito, Angelo Borsarelli Carvalho; Delamain, Márcia Torresan; Natal, Rodrigo de Andrade; Soares, Fernando Augusto; Colleoni, Gisele W. B.; Souza, Cármino Antonio De; Vassallo, José; Lima, Carmen Sílvia Passos

doi:10.1038/bcj.2016.76

Cited by 7 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 However, VEGF also increases interleukin-6 secretion by endothelial and BM stromal cells, which stimulates MM cell growth, with consequent relapse of disease and death. 1 We observed herein that BM of MM patients carrying the VEGF c.-1154GG genotype have increased MVD, and we have also recently shown that follicular lymphoma MVD was increased in patients with the CC genotype of VEGF c.-2595C>A SNP; 14 these findings support associations between VEGF SNPs and MVD in lymphoproliferative disorders. In addition, GSTM1 gene stimulates AG due to its effect on the HIF-1α metabolic pathway, 4 and hyperexpression of HIF-1α was associated with MM progression.…”

supporting

confidence: 77%

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

et al. 2017

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 77%

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…In fact, the association of -2578 CC or CA genotypes and increased risk of HGG was expected, since the ''C'' allele has been related to higher VEGFA production 19 and a higher risk of other tumors, such as lymphoma and multiple myeloma. 34,35 Thus, individuals harboring the ''C'' allele of VEGFA-2578C/A may produce more blood vessels than those with the AA genotype and may have a higher risk of HGG as a consequence.…”

Section: Discussionmentioning

confidence: 99%

Associations ofVEGFAandKDRsingle-nucleotide polymorphisms and increased risk and aggressiveness of high-grade gliomas

et al. 2019

View full text Add to dashboard Cite

Angiogenesis, induced by the vascular endothelial growth factor A through its ligation to the vascular endothelial growth receptor 2, has been described as a crucial point in high-grade glioma development. The aim of this study was to evaluate the influence of VEGFA–2578C/A, −2489C/T, −1154G/A, −634G/C, and −460C/T, and KDR–604T/C, −271G/A, +1192G/A, and +1719A/T single-nucleotide polymorphisms on risk and clinicopathological aspects of high-grade glioma. This case–control study enrolled 205 high-grade glioma patients and 205 controls. Individuals with VEGFA–2578 CC or CA, VEGFA–1154 GG, VEGFA–634 GC or CC, and VEGFA–460 CT or TT genotypes were under 2.56, 1.53, 1.54, and 1.84 increased risks of high-grade glioma, compared to others, respectively. And 1.61, 2.66, 2.52, 2.53, and 2.02 increased risks of high-grade glioma were seen in individuals with VEGFA–2578 CC plus VEGFA–1154 GG, VEGFA–2578 CC or CA plus VEGFA–634 GC or CC, VEGFA–2578 CC or CA plus VEGFA–460 CT or TT, VEGFA–1154 GG or GA plus VEGFA–634 GC or CC, and VEGFA 634 GC or CC plus VEGFA–460 CT or TT combined genotypes, respectively, when compared to others. The “CAGT” haplotype of KDR single-nucleotide polymorphisms was more common in patients with grade IV than in those with grade III tumors, and individuals carrying this haplotype were at 1.76 increased risk of developing grade IV tumors than others. We present, for the first time, preliminary evidence that VEGFA–2578C/A and VEGFA–1154G/A single-nucleotide polymorphisms increases high-grade glioma risk, and “CAGT” haplotype of the KDR gene alters high-grade glioma aggressiveness and risk of grade IV tumors in Brazil.

show abstract

“…The genetic information of the VEGFA SNPs was obtained from Haploreg 4.1, the SNP database of the National Center for Biotechnology Information. Eleven VEGFA SNPs (rs2010963, rs699947, rs10434, rs25648, rs3024987, rs3025022, rs3025035, rs3025039, rs998584, rs6905288, and rs881858) were selected and genotyped to investigate their associations with BRONJ development [29][30][31][32][33][34][35][36]. These SNPs were analyzed by SNaPShot Multiplex kits (ABI, Foster City, CA, USA) according to the manufacturer's instructions.…”

Section: Genotypingmentioning

confidence: 99%

Machine Learning Approaches for Predicting Bisphosphonate-Related Osteonecrosis in Women with Osteoporosis Using VEGFA Gene Polymorphisms

Kim

Yee

et al. 2021

JPM

View full text Add to dashboard Cite

Objective: This nested case–control study aimed to investigate the effects of VEGFA polymorphisms on the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in women with osteoporosis. Methods: Eleven single nucleotide polymorphisms (SNPs) of the VEGFA were assessed in a total of 125 patients. Logistic regression was performed for multivariable analysis. Machine learning algorithms, namely, fivefold cross-validated multivariate logistic regression, elastic net, random forest, and support vector machine, were developed to predict risk factors for BRONJ occurrence. Area under the receiver-operating curve (AUROC) analysis was conducted to assess clinical performance. Results: The VEGFA rs881858 was significantly associated with BRONJ development. The odds of BRONJ development were 6.45 times (95% CI, 1.69–24.65) higher among carriers of the wild-type rs881858 allele compared with variant homozygote carriers after adjusting for covariates. Additionally, variant homozygote (GG) carriers of rs10434 had higher odds than those with wild-type allele (OR, 3.16). Age ≥ 65 years (OR, 16.05) and bisphosphonate exposure ≥ 36 months (OR, 3.67) were also significant risk factors for BRONJ occurrence. AUROC values were higher than 0.78 for all machine learning methods employed in this study. Conclusion: Our study showed that the BRONJ occurrence was associated with VEGFA polymorphisms in osteoporotic women.

show abstract

Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients

Cited by 7 publications

References 15 publications

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

Associations ofVEGFAandKDRsingle-nucleotide polymorphisms and increased risk and aggressiveness of high-grade gliomas

Machine Learning Approaches for Predicting Bisphosphonate-Related Osteonecrosis in Women with Osteoporosis Using VEGFA Gene Polymorphisms

Contact Info

Product

Resources

About